An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

NCT01876849 on ClinicalTrials.gov · last registry update 2015-02-24

Finished July 2008, after enrolling 275 people. Primary outcome, as filed: Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 275
Started: 2003-12
Primary completion: 2008-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.